XOMA(US:XOMA) Globenewswire·2026-01-13 21:34Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving XOMA Royalty Corporation and its officers or directors [1] Group 1: Company Overview - XOMA Royalty Corporation is listed on NASDAQ under the ticker symbol XOMA [1] - The company is involved in a partnership with Rezolute, Inc. for the development of medical treatments [3] Group 2: Recent Developments - Rezolute, Inc. announced that its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism did not meet its primary endpoint, showing only a 45% reduction in hypoglycemia events at the highest dose, which was not statistically significant compared to a 40% improvement in the placebo group [3] - The study also failed to meet its key secondary endpoint, with a 25% reduction in time spent in hypoglycemia at the 10 mg/kg dose, again not statistically significant compared to a 5% increase in the placebo group [3] - Following this announcement, XOMA's stock price dropped by $7.82 per share, or 22.76%, closing at $25.39 per share on December 19, 2025 [3]